Pilot study evaluating the efficacy of... — Clinical Trial Details

Open-label, non-randomised, single-group Phase II study in older adults (≥65) with MDD (n=24). Phase 1: all participants receive subcutaneous ketamine 0.3 mg/kg then 0.6 mg/kg one week apart; responders may enter Phase 2 maintenance.

Primary outcome is change in Geriatric Depression Scale (GDS). Phase 2 maintenance dosing is individualised (1–2x/week up to 3 months). Safety and tolerability monitored throughout.

To be included in the study, participants must meet all of the following inclusion criteria:
1. Capable of understanding and signing an informed consent
2. Aged > 65 years on the day of consent.
3. Psychiatric history: Participants will be assessed using DSM-5 criteria (APA, 2013) via a standardized clinical psychiatric interview conducted by a trained examiner.
4. Patients with MDD: Baseline GDS > 9.

To be included in the study, participants must meet none of the following exclusion criteria:
1. Participants who, in the opinion of the investigator, do not understand the information and procedures of the study, or would not be compliant with them (in particular the study restrictions and risks involved).
2. Any participant for whom the investigator believes, for any reason, that participation would not be an acceptable risk.
3. Patients with severe unstable acute or chronic medical illnesses.
4. Patients with current active suicidal ideation.
5. Any history of an additional axis I diagnosis (not including adjustment disorder, simple phobia, dysthymia or comorbid anxiety) is exclusionary.

Company

Product

Legal

Pilot study evaluating the efficacy of subcutaneous ketamine for the treatment of depression in the elderly

Detailed Description

Study Protocol

Preparation

Dosing

Locations

Integration

Therapeutic Protocol

Study Arms & Interventions

SC ketamine

Interventions

Participants

Inclusion Criteria

Exclusion Criteria

Study Details